NasdaqGS - Delayed Quote USD

Monte Rosa Therapeutics, Inc. (GLUE)

5.85 -0.07 (-1.18%)
At close: April 19 at 4:00 PM EDT
5.85 0.00 (0.00%)
After hours: April 19 at 4:03 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Markus Warmuth M.D. President, CEO & Director 901.35k -- 1972
Dr. Owen B. Wallace Ph.D. Chief Scientific Officer 630.68k -- 1969
Dr. Filip Janku M.D., Ph.D. Chief Medical Officer 658.66k -- 1975
Ms. Jennifer Champoux Chief People & Operations Officer -- -- --
Dr. Sharon Townson Ph.D. Chief Technology Officer -- -- 1975
Dr. John C. Castle Ph.D. Chief Data & Information Officer -- -- 1972
Mr. Andrew Funderburk Senior VP and Head of IR & Strategic Finance -- -- --
Mr. Philip Nickson J.D., Ph.D. General Counsel -- -- 1979
Mr. Magnus Walter DPHIL Senior Vice President of Drug Discovery -- -- --
Mr. Edmund Dunn Vice President & Corporate Controller -- -- 1966

Monte Rosa Therapeutics, Inc.

321 Harrison Avenue
Suite 900
Boston, MA 02118
United States
(617) 949-2643 https://www.monterosatx.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
133

Description

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Corporate Governance

Monte Rosa Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 9. The pillar scores are Audit: 9; Board: 9; Shareholder Rights: 8; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Related Tickers

EWTX Edgewise Therapeutics, Inc.
15.23
-1.42%
 
TYRA Tyra Biosciences, Inc.
14.98
+2.18%
 
IPSC Century Therapeutics, Inc.
3.0900
+3.87%
 
IKNA Ikena Oncology, Inc.
1.3300
+5.56%
 
DSGN Design Therapeutics, Inc.
3.7000
-1.07%
 
KYMR Kymera Therapeutics, Inc.
33.97
-3.27%
 
TNYA Tenaya Therapeutics, Inc.
4.3200
+0.70%
 
ENTA Enanta Pharmaceuticals, Inc.
13.32
+0.68%
 
ORIC ORIC Pharmaceuticals, Inc.
9.19
-3.36%
 
FHTX Foghorn Therapeutics Inc.
5.30
-4.16%